ENDRA Life Sciences Inc. Q1 FY2023 earnings call

• Francois Michelon reported completion of clinical data collection to support de novo request to US FDA for TAEUS, with over 100 subject scans performed, expecting midyear de novo submission. TAEUS addresses unmet needs in NAFLD diagnosis. - Intellectual property grew with 7 newly issued patents, total portfolio 63 issued patents and 31 filed assets. - Post-quarter, upsized capital raise of $4.5M in net proceeds. - Michael Thornton discussed clinical progress: deployed user training and guidance tools, over 100 exams with tool, feedback positive, upcoming FDA submission review, clinical abstract accepted for EASL. - Irina Pestrikova reviewed financials: Q1 2023 operating expenses $2.9M, net loss per share $0.93, cash $2.4M as of March 31, 2023.

No specific product segment financial performance with revenue contribution % provided in the transcript.

• Expect to submit de novo request to FDA midyear. - Leverage clinical data to arm sales team for European commercial efforts. - Maintain marketing activities to expand TAEUS awareness, including conference participation. - Recent capital raise positions company to fund key milestones like FDA submission and commercial deployment in Europe.

Q: Edward Woo with Ascendiant Capital asked about marketing in Europe and what's learned that could inform US approval.

A: Francois Michelon responded that the market is broader than initially thought, with interest from gastrohepatologists and endocrinologists, and Michael Thornton added on impact of GLP-1 drugs on fatty liver health.